Taysha Gene Therapies (TSHA) Misses Q4 EPS by 7c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q4 EPS of ($1.32), $0.07 worse than the analyst estimate of ($1.25).

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• Investing.com’s stocks of the week
• Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting